By Govind Rammurthy, CEO and Managing Director, eScan Every year, World Backup Day reminds us to back up our data. Every year, most people ignore it. Then ransomware hits, a [...] The post From backup to resilience: A 2026 data strategy imperative appeared first on Express Computer .
Japan is seeking to work more closely with Indonesia on energy security, Prime Minister Sanae Takaichi said, as global concerns over supply ...
Grocery prices are still stretching fixed incomes.
As the Strait of Hormuz crisis roils world energy markets, China and the US still have strong potential to work together to find solutions, according to a researcher with a Chinese think tank. Wang Lining – who heads the oil market department at the Economics and Technology Research Institute under state-run China National Petroleum Corporation – also said Washington’s change in direction on energy diplomacy was a “reminder” that Beijing could play a bigger role in global governance. Wang made...
Canada’s economy should be the envy of the world. Instead, we’re falling behind, constrained by a system that struggles to turn opportunity into action. Our country has the makings of an economic powerhouse — private-sector capacity and expertise to build, an educated workforce, stable institutions, rule of law and abundant natural resources. But the investment [...]
Hong Kong, China, March 31, 2026 (GLOBE NEWSWIRE) -- The board of directors (the "Board") of Seres Group Co., Ltd. (the "Company"; Stock Code: 601127.SS), a leading luxury new energy vehicle (NEV) manufacturer in China, today announced the audited consolidated results of the Company and its subsidiaries (collectively, the "Group") for the year ended 31 Dec 2025 (the "Reporting Period"). During the Reporting Period, the Group achieved revenue of approximately RMB165.05 billion, up 13.7% year-on-year, while net profit attributable to shareholders reached approximately RMB5.96 billion. The gross profit margin of new energy vehicles was 28.8%, ranking among the highest in the industry, reflecting the Group's strong pricing power, optimized product mix and cost efficiency in the premium segment. R&D investment reached RMB12.51 billion, up 77.4% year-on-year, providing solid technical support for product innovation and market expansion. AITO Achieved Sustained Growth, Leading China's Luxury Vehicle Market The Group's record revenue reflects the continued success of its premium positioning and operational strength. Driven by strong demand for its high-end AITO series, the Group continued to explore opportunities in the global market and promoted the coordinated development of various business segments, achieving revenue of RMB165.05 billion, a new record high and realizing profitability for two consecutive years. Notably, AITO, the Group's high-end brand, delivered over 420,000 vehicles in 2025, ranking as the best-selling Chinese luxury car brand in the domestic market. Key models continued to perform strongly: The AITO M9 delivered over 110,000 units throughout the year, ranking first in its segment for two consecutive years in 2024 and 2025; The AITO M8 achieved annual deliveries exceeding 150,000 units, maintaining the top sales position in the RMB400,000 segment since its launch; The AITO M7 delivered over 110,000 units for the year and was awarded ... Full story available on Benzinga.com
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are at an important juncture for the belapectin development program. During 2025, we made meaningful progress advancing the belapectin program and continuing our analysis of the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. We are encouraged by the signals observed, including additional biomarkers from the NAVIGATE dataset, and remain focused on evaluating the data as we engage with regulators, potential partners, and leading experts to determine the optimal path forward for the program. Importantly, we also improved the Company's financial position during the year, including securing an additional $10 million line of credit from our Chairman, Dick Uihlein, to extend our projected cash runway through April 2027. Also, just very recently, we have strengthened our Board with the appointment of Dr. Henry Brem, an internationally recognized neurosurgeon-scientist and leader in translational medicine, whose clinical development experience will be valuable as we advance the program. With no approved therapies currently available for patients with MASH cirrhosis, we believe belapectin has the potential to address a significant unmet medical need and look forward to discussing the program with FDA." Khurram Jamil, M.D., Chief Medical Officer, added "The NAVIGATE dataset continues to provide encouraging insights supporting belapectin's potential role in patients with MASH cirrhosis and portal hypertension. In addition to the previously reported clinical finding of reduced varices incidence in the per-protocol population, additional biomarker analyses have demonstrated consistent signals across specialized markers of fibrosis and noninvasive measures of liver stiffness, supporting belapectin's potential antifibrotic activity and disease-modifying effect. These findings have been well received by the scientific community and were recently discussed by leading hepatology experts during our March 10, 2026 virtual KOL event, where the data were reviewed in the context of disease progression and portal hypertension category risk in MASH cirrhosis. Taken together, these results further strengthen the biological rationale for galectin-3 inhibition and support continued evaluation of belapectin as a potential therapy for patients with MASH cirrhosis, a population for whom there are currently no approved treatment options. We are excited about our upcoming FDA meeting in the second quarter of 2026 to align on the next steps for advancing the program. We are pleased to announce that multiple abstracts from the NAVIGATE program have been accepted for presentations at the upcoming EASL Congress, including one oral presentation. This builds on our momentum from last year's late-breaker presentation at EASL and oral presentation at AASLD 2025 and reflects the continued interest from the scientific community in our unique and comprehensive dataset." Belapectin Program Highlights Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein involved in fibrosis and inflammation associated with MASH and portal hypertension. MASH Cirrhosis NAVIGATE Phase 2b/3 trial ( NCT04365868 ) is a global, randomized, double-blind, placebo-controlled study evaluating belapectin administered intravenously at 2 mg/kg or 4 mg/kg of lean body mass (LBM) versus placebo every two weeks for 18 months for the prevention of esophageal varices in patients with MASH cirrhosis. The NAVIGATE trial demonstrated: In the intent-to-treat population (n=355), the incidence of varices at 18 months was 43.2% lower in patients treated with belapectin 2 mg/kg compared with placebo, although the composite endpoint did not reach statistical significance. In the per-protocol population (n=287), belapectin 2 mg/kg reduced the incidence of varices by 49.3% versus placebo (nominal p = 0.04). In U.S. patients within the per-protocol population (n=186), belapectin 2 mg/kg reduced the incidence of varices by 68.1% compared with placebo (p = 0.02). Safety results showed a similar proportion of treatment-emergent adverse events, serious adverse events, and discontinuations across treatment groups, with no drug-related serious adverse events observed. Additional 18-month NAVIGATE biomarker analyses presented in 2025 demonstrated consistent effects across multiple non-invasive markers of fibrosis and disease progression, including FibroScan® liver stiffness measurement, ELF score, and PRO-C3, further supporting belapectin's potential antifibrotic and disease-modifying activity in patients with compensated MASH cirrhosis and portal hypertension. Additional mechanistic analyses, including YKL-40 and PRO-C4, further supported belapectin's biological activity, with findings consistent with reduced inflammation and fibrogenesis. Analyses using validated Baveno VII criteria suggested belapectin treatment was associated with improvements in portal hypertension risk categories and a reduced risk of hepatic decompensation compared with placebo. In March 2026, the Company hosted a virtual KOL event featuring leading hepatology experts who reviewed additional NAVIGATE biomarker findings and discussed their implications for disease progression and portal hypertension risk in MASH cirrhosis. The Company will present new NAVIGATE trial analyses at EASL 2026 (May 27–30, 2026), including an oral presentation on reduced varices based on favorable changes in markers of fibrosis formation and resolution (PRO-C3/CTX-III), and a poster presentation on risk reduction in clinically significant portal hypertension in advanced MASH cirrhosis. Full Year 2025 Financial Highlights As of December 31, 2025, the Company had $17.7 million of unrestricted cash and cash equivalents in addition to $10 million available under a line of credit provided by our chairman to fund future operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through April 2027. Research and development expenses for the year ended December 31, 2025 were $14.3 million compared with $36.6 million for the year ended December 31, 2024. The decrease was primarily due to costs related to our NAVIGATE clinical trial and other supportive activities. General and administrative expenses for the year ended December 31, 2025 were $5.8 million, compared to $5.9 million for the year ended December 31, 2024. For the year ended December 31, 2025, the Company reported a net loss applicable to common stockholders of $31.0 million, or ($0.48) per share, compared to a net loss applicable to common stockholders of $47.2 million, or ($0.76) per share, for the year ended December 31, 2024. The decrease is largely due to a decrease in research and development costs due to the conclusion of the NAVIGATE trial. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov . About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical need and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect", "look forward", "believe", "hope" and others. They ... Full story available on Benzinga.com
Vancouver, BC, March 31, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) today announced its wholly-owned subsidiary Rocket Doctor Inc (“Rocket Doctor”) has appointed two additional senior leaders to its team as part of a strategic initiative to advance its digital health platform and marketplace, strengthen product and engineering capabilities, and support continued growth across North America. Dr. Anikia Nelson joins as Director of Product, and Bilal Malik as Director of Engineering, where they will be responsible for overseeing and enhancing product direction, platform innovation, scalability, and platform interoperability - liaising between our clinical and technology teams.
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer
The discount shopping platform is officially live following a quiet soft launch.
CARSON CITY, Nev. , March 31, 2026 /PRNewswire/ -- American Lithium Minerals Inc. (OTC: AMLM ) ("AMLM" or the "Company"), a dynamic exploration-stage company focused on critical metals, precious metals, and rare earth elements is pleased to announce that it has completed the acquisition of the Higginsville Project , a package of four granted prospecting licenses located in one of Western Australia's most prolific gold-producing regions. ... Full story available on Benzinga.com
The festival is taking place this year from April 10 to 12 and from April 17 to 19.